Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

PBS Listing Of Antifungal Suspension Welcomed By Paediatricians
General Practitioners and specialists will be able to prescribe VFEND® (voriconazole) oral suspension for immuno-suppressed adolescents and children following its listing on the Pharmaceutical Benefits Scheme (PBS) from 1 August 2009.
generic viagra online
DNA Binding Compound That Kills Bacteria In 2 Minutes Could Lead To New Antibiotics
A synthetic DNA binding compound has proved surprisingly effective at binding to the DNA of bacteria and killing all the bacteria it touched within two minutes. The DNA binding properties of the compound were first discovered in the Department of Chemistry at the University of Warwick by Professor Mike Hannon and Professor Alison Rodger (Professor Mike Hannon is now at the University of Birmingham). However the strength of its antibiotic powers have now made it a compound of high interest for University of Warwick researchers working on the development of novel antibiotics.
News of the day
Docs Plan Strike, Issue Own Declaration Of Independence
On Independence Day, Doctors on Strike for Freedom in Medicine will take on the mission of preserving, protecting, and promoting freedom in healthcare. This nonprofit organization"s web site (http://www.doctorsonstrike.com) states that their most pressing goal is to mobilize doctors to go on strike against any new government healthcare plans. Their long-term objective is to supply healthcare providers with intellectual ammunition to win the "philosophical war" against statism in medicine.
Public Health

China Sky One Medical, Inc. Obtains SFDA Approval For Diclofenac Sodium Eye Drops

China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People"s Republic of China ("PRC"), announced that it obtained approval from the State Food and Drug Administration (SFDA) in China for the production of Diclofenac Sodium eye drops. The document number for the drug is 2009S02063. Diclofenac Sodium eye drops are used to treat uveitis, keratitis and sclerotitis, conditions that affect the eye. They are able to inhibit new formations of unwanted vessels in the cornea and to reduce inflammation after various types of eye operations, such as laser treatment, cataract surgery and intraocular lens operations. Diclofenac Sodium eye drops also help cure seasonal conjunctivitis and allergic conjunctivitis. The generic drops are prescription medicines that are included in medical insurance catalogues in China and they will be available to consumers from China Sky One Medical in August 2009. Management expects that there will be a strong market for Diclofenac Sodium eye drops and that they will contribute $0.5 million to revenues in the first year of sales. "China Sky One Medical has received production approvals for seven new drugs in 2009 and we greatly appreciate the strong efforts by our R&D and sales teams in bringing new drugs to market," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "With the intelligence from our sales team, our R&D professionals can identify drugs that have strong market potential. We feel confidence that our robust product portfolio will create long term value for our shareholders." About China Sky One Medical, Inc. China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue . Safe Harbor Statement Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People"s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time. China Sky One Medical, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009